« Back to Farmacia Journal 5/2025

EFFECTIVENESS AND SAFETY OF OMEPRAZOLE IN TREATING FUNCTIONAL DYSPEPSIA: A META-ANALYSIS

RONG HU 1, WEI LU 2, HUA CHEN 1, YANMIN CHEN 1, JIXING ZHONG 1, WEN LEI 2*

1 Department of General Surgery, The First People’s Hospital of Changde, Changde 415000, Hunan, China
2 Operating Room, The First People’s Hospital of Changde, Changde 415000, Hunan, China

Download Full Article PDF

This study systematically evaluated the efficacy of omeprazole in treating functional dyspepsia, a common gastrointestinal disorder with high recurrence and significant impact on quality of life. Randomized controlled trials published up to June 1, 2024, were searched in multiple databases. Study quality was assessed using a modified Jadad scale and Cochrane standards, and meta-analysis was performed with RevMan 5.3. Nine studies involving 3,189 patients were included: 1,841 received omeprazole and 1,348 received placebo. Omeprazole showed significantly higher clinical efficacy and symptom improvement compared with placebo (OR = 2.03, 95% CI = 1.34 - 3.08, p = 0.0009; OR = 0.83, 95% CI = 0.72 - 0.97, p = 0.02). Additionally, adverse reactions were lower in the omeprazole group (RD = −0.02, 95% CI = −0.04 to −0.00, p = 0.03). Overall, omeprazole is more effective than placebo for functional dyspepsia, improving symptoms with fewer side effects. Larger, high-quality studies are needed to further confirm these findings.